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ABSTRACT:
With the advent of targeted therapies directed towards folate receptor alpha, with 
several such agents in late stage clinical development, the sensitive and robust 
detection of folate receptor alpha in tissues is of importance relative to patient 
selection and perhaps prognosis and prediction of response. The goal of the present 
study was to evaluate the expression of folate receptor alpha in non-small cell lung 
cancer specimens to determine its frequency of expression and its potential for 
prognosis. The distribution of folate receptor alpha expression in normal tissues as 
well as its expression and relationship to non-small cell lung cancer subtypes was 
assessed by immunohistochemistry using tissue microarrays and fine needle aspirates 
and an optimized manual staining method using the recently developed monoclonal 
antibody 26B3. The association between folate receptor alpha expression and clinical 
outcome was also evaluated on a tissue microarray created from formalin fixed paraffin 
embedded specimens from patients with surgically resected lung adenocarcinoma. 
Folate receptor alpha expression was shown to have a high discriminatory 
capacity for lung adenocarcinomas versus squamous cell carcinomas. While 74% 
of adenocarcinomas were positive for folate receptor alpha expression, our results 
found that only 13% of squamous cell carcinomas were FRA positive (p<0.0001). In 
patients with adenocarcinoma that underwent surgical resection, increased folate 
receptor alpha expression was associated with improved overall survival (Hazard 
Ratio 0.39, 95% CI 0.18-0.85). These data demonstrate the diagnostic relevance 
of folate receptor alpha expression in non-small cell lung cancer as determined by 
immunohistochemistry and suggest that determination of folate receptor alpha 
expression provides prognostic information in patients with lung adenocarcinoma.
INTRODUCTION
Folate receptor alpha (FRA), a 
glycosylphosphatidylinositol (GPI)-anchored cell surface 
glycoprotein, is a member of a family of folate receptors 
that mediate folate transport into cells [1]. The family 
consists of four isoforms (alpha, FRA; beta, FRB; gamma, 
FRG and delta, FRD). The FRA and FRB isoforms are 
highly homologous, GPI-anchored proteins that have 
high affinity (KD ~1 nM) for 5-methyltetrahydrofolate, 
the predominant plasma folate [1]. These two family 
members, however, have distinct patterns of expression 
in normal and malignant tissues. Previous studies have 
found FRA to be mainly expressed on the apical surface Oncotarget 2012; 3:  414-425 415 www.impactjournals.com/oncotarget
of a limited subset of polarized epithelial cells in normal 
tissue and in certain malignancies of epithelial origin 
[2]. FRB expression has been reported to be restricted to 
hematopoietic cells of myelogenous lineage [3].
Due to its restricted expression pattern in normal 
and malignant cells, FRA is the most widely studied 
member of this folate receptor family [4]. Previous studies 
have found it to be highly expressed in non-mucinous 
(serous) ovarian and endometrial carcinomas, lung 
adenocarcinoma and to a lesser extent in breast cancer. 
Moreover, several studies have suggested that levels of 
FRA expression are associated with tumor stage and/or 
survival in some cancers, including ovarian cancer and 
lung adenocarcinoma [5-8].
The potential to exploit the differential expression 
of FRA for targeted cancer therapy has long been 
appreciated. Two primary approaches have been explored; 
one involving targeted drug delivery via folate-conjugated 
therapeutic compounds [9-12], and the other involving 
direct targeting and tumor cell death via humanized anti-
FRA monoclonal antibodies [13-15]. Both approaches 
have advanced to late-stage clinical development, and 
anti-FRA monoclonal antibody therapy with farletuzumab 
is in clinical trials in both ovarian cancer and non-small 
cell lung adenocarcinoma.
Identification  of  patients  who  may  benefit  from 
FRA-targeted therapy may support the development 
of such therapeutics, particularly in cancers where the 
frequency and degree of expression is not ubiquitous 
or variable [16-18]. Detection of FRA on formalin-
fixed  paraffin  embedded  (FFPE)  tissue  sections  via 
immunohistochemistry (IHC) requires highly sensitive and 
specific reagents. The development and characterization 
of novel, high-affinity FRA-specific antibodies that can 
be used in multiple diagnostic platforms, including IHC, 
has recently been described [19]. One unique clone, 
monoclonal antibody 26B3.F2 (MAb 26B3) displayed 
high-affinity FRA binding and the ability to recognize 
FRA in both its native and denatured forms [19]. 
Previous reports that FRA expression may vary by 
non-small cell lung cancer (NSCLC) histological subtype 
and that expression levels may be associated with disease 
stage or survival in lung adenocarcinoma suggest that 
FRA may be a useful diagnostic and prognostic marker 
[5, 6]. There is increasing evidence that histological 
subtype is an important determinant of treatment response 
in NSCLC.  For patients with lung adenocarcinoma, 
multiple new treatment options have become available in 
the last few years, including agents such as pemetrexed 
and bevacizumab. Thus, standard-of-care practice now 
requires the performance of an expanded panel of IHC 
analyses in all cases of newly diagnosed NSCLC in order 
to distinguish between the major histologic subtypes; 
however this distinction can be challenging, particularly 
in small biopsy or cytological (e.g. fine needle aspiration 
or FNA) specimens. 
Here we report the IHC characterization of MAb 
26B3 in NSCLC and describe its ability to reliably 
discriminate between lung adenocarcinoma and squamous 
cell carcinoma. Furthermore, we describe the role of 
tumor FRA expression in the prognosis of patients with 
surgically resected lung adenocarcinoma.
MATERIALS AND METHODS
Tissue Microarrays
Normal tissue (catalog # FDA806-1; 3 individuals 
per tissue type) and lung carcinoma (catalog # BC041114; 
90 cases, duplicate cores) TMAs were obtained from US 
Biomax, Inc. (Rockville, MD). These TMAs were used 
to define the distribution of FRA expression on a wide 
range of normal tissues and various histological types of 
lung cancer.  To assess FRA expression as a prognostic 
indicator, an analysis was performed on a separate TMA 
constructed from tissues obtained from 68 subjects with 
newly diagnosed lung adenocarcinoma recruited from the 
University of Pennsylvania (Penn) from 2003 through 
2006. The Penn TMA was constructed from FFPE archival 
tumor and adjacent normal specimens collected at the time 
of surgical resection. All tumors were reviewed by a lung 
pathologist for confirmation of histologic subtype. Three 
samples (0.6 mm cores) of representative tumor tissue 
and adjacent normal tissue from each subject and normal 
control tissues were prepared using a manual arrayer 
(Beecher Instruments, Inc., Sun Prairie, WI).  A total of 
15 subjects were excluded from the survival analysis 
because they had received treatment with neoadjuvant 
chemotherapy prior to surgery (6 subjects), lacked tumor 
cells in the TMA core (5 subjects) or lacked survival data 
(4 subjects). No other subjects received any therapy prior 
to surgical resection. Clinical outcome data was collected 
prospectively via clinic follow-up, review of electronic 
medical records, direct phone contact, and the Social 
Security Death Index (SSDI). Tissue samples from nine 
additional subjects with lung adenocarcinoma diagnosed 
by fine needle aspiration (FNA) of a subcarinal, hilar or 
paratracheal lymph node and containing sufficient material 
for preparation of paraffin-embedded cell blocks were 
used to determine the suitability of FNAs for the detection 
of FRA by IHC using MAb 26B3. The Penn Institutional 
Review Board approved this study and all subjects 
provided written informed consent for use of their tissues.
Immunohistochemistry
IHC was performed using FFPE specimens and a 
MACH4 Universal HRP-Polymer Detection Kit (Biocare 
Medical, Concord, CA). FFPE specimens were sectioned 
at 5µm onto positively-charged glass slides and heated for Oncotarget 2012; 3:  414-425 416 www.impactjournals.com/oncotarget
approximately 60min at 60°C. Slides were deparaffinized 
in 3 sequential baths of xylene for 3min each, transferred 
to three sequential baths of 100% alcohol for 3min each, 
followed by three sequential baths of 95% alcohol for 
3min each and then rinsed for 5min in deionized (DI) 
water. Slides were then pretreated in Diva heat-induced 
epitope retrieval solution (Biocare Medical) diluted 1:10 
in DI water and placed inside a pressurized decloaking 
chamber  already  filled  with  500mL  of  DI  water.  For 
antigen retrieval, slides were incubated for 15min inside 
the decloaking chamber in which pressurized incubation 
reaches a maximum of 125°C at 16 PSI for 30sec and then 
cooled for 15min down to 95°C. After cooling to room 
temperature (RT), slides were washed in 3 sequential 
baths of Tris Buffered Saline/0.1% Tween-20 wash buffer 
(TBST) for 3min each and subsequently placed into 
Peroxidase-1 (Biocare Medical) blocking solution for 
5min at RT. After washing in TBST as above, Background 
Sniper (Biocare Medical) serum-free universal blocking 
reagent was applied for 10min at RT. Slides were then 
incubated  with  purified  MAb  26B3.F2[19]  or  clone 
BN3.2[20] at 2.5µg/mL diluted in Antibody Diluent 
(Dako North America, Inc., Carpinteria, CA) or Universal 
Negative Control [mouse ready-to-use negative control 
antibody (Dako, for negative isotype tissue)] for 60min 
at RT. After washing, slides were incubated with MACH4 
Mouse  Probe  Primary Antibody  Enhancer  for  15min, 
followed by Polymer-HRP reagent for 20min, developed 
with a 3,3′-diaminobenzidine tetrahydrochloride (DAB) 
solution (Dako) for 5min and counterstained with 
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Figure 1: Staining Patterns and Intensities for FRA Expression in Lung Adenocarcinoma samples. The figure illustrates 
and highlights the different staining patterns observed and the magnification required to accurately assess staining intensity.
A. Lung adenocarcinoma with 3+, strong membrane staining on the luminal and lateral cell borders. Tumor cells in cross section reveal a 
honey-comb pattern (center field). Membrane staining is clearly visible by 10x objective. A weak cytoplasmic staining is present as well 
(10x). 
B. Lung adenocarcinoma. Clusters of tumor cells demonstrate 2+, moderate membrane staining on the luminal and lateral cell borders. 
Membrane staining is weaker and thinner than 3+ seen in Panel A (20x). 
C. Poorly differentiated adenocarcinoma. Tumor cells present with weak, incomplete membrane staining (40x). 
D. Lung squamous cell carcinoma. Solid sheet of tumor cells with necrotic, keratinized cells in the upper field. No membrane or cytoplasmic 
staining is seen (20x). Oncotarget 2012; 3:  414-425 417 www.impactjournals.com/oncotarget
hematoxylin (Dako) for 2min, all incubations being 
performed at RT. Scoring for staining was performed by a 
single board-certified pathologist, using customary scoring 
for intensity and the percent of the tumor stained at each 
intensity.
IHC Scoring method
In this study, FRA IHC membrane and cytoplasmic 
staining intensities were scored as 0, no staining; 1+, 
weak; 2+, moderate and 3+, strong (Figure 1). The percent 
of cells in each core stained by MAb 26B3 (or an unrelated 
anti-FRA MAb called clone BN3.2) was also determined 
and recorded (see below). Samples were analyzed under 
4x, 10x, 20x and 40x objectives. 3+ strong membrane 
staining was readily visualized under 4x and confirmed 
at 10x. 2+ moderate membrane staining was visible 
at 10x and confirmed at 20x and 1+ weak membrane 
staining required 20x or 40x objectives. In the presence 
of 3+ staining, the membrane was thick occurring at 
apical and lateral cell borders. In tangential sections, a 
complete circumferential pattern was evident (Figure 
1A). 2+ membrane staining was weaker in intensity and 
thinner than 3+, usually localized on the apical luminal 
borders and occasionally on lateral cell borders (Figure 
1B). 1+ weak membrane staining was generally limited 
to the luminal borders (Figure 1C). The accompanying 
cytoplasmic staining was variable, depending on the type 
of tumor, and although recorded, was not assessed further.
Statistical Analyses
Criteria for a Positive Staining Result and TMA Core 
Rejection
A sample (TMA core or whole section) was 
considered positive for FRA expression if the percentage 
of the tumor area considered by the reading pathologist 
to be positive for membranous staining was greater than 
or equal to 5% at any intensity. A TMA core was rejected 
and therefore not included in the analyses if the reading 
pathologist determined it was either missing entirely 
(empty core), was composed of necrotic tissue or was 
deemed to represent normal tissue. Histopathologic 
diagnosis of cores was made by the reading pathologist.
The M-score: A Semi-Quantitative Staining Algorithm
A metric for staining (M-score) of each sample was 
defined as follows: 
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In the equation, xij is the percentage of tumor stained 
at intensity j for patient i and wj is the absolute value 
of the intensity (ranging from 0 to 3+). The metric has 
a theoretical range from zero (no positive staining) to 
fifty (100% of cells staining at 3+ intensity). As such, 
the M-score is a weighted score for FRA IHC tumor cell 
membrane staining that captures both the proportion of 
FRA positive cells and staining intensity.  
M-scores for each patient were averaged over 
multiple TMA cores, where appropriate. If a determination 
(core) was void of results, i.e. no tumor present or 
necrotic tissue, the M-score was assigned to the non-void 
determinations. 
The practical application of the above equation is 
presented below:
3+ 2+ 1+ 0 M-Score
x = 40 y = 30 z = 10 20 M = (3x + 2y +z)/6
3 x 40 = 120 2 x 30 = 60 1 x 10 = 10 - (120+60+10)/6=31.67
Here, x = % of tumor stained with intensity 3+; y 
= % of tumor stained with intensity 2+; z = % of tumor 
stained with intensity 1+.
The positivity rate for FRA expression within a given 
histology was calculated as the proportion of samples 
that were stained positive according to the definition of 
a positive result (≥5% of the total tumor cells staining). 
Exact  binomial  confidence  intervals  were  determined 
using the methods of Clopper and Pearson.[21] 
Summary statistics are presented for all demographic 
variables and for the M-score. Differences for mean values 
were determined using one-way ANOVA with post-hoc 
tests controlling for overall type I error. Differences in 
mean values were statistically different if the p-value 
associated with the test was less than the Bonferroni 
adjusted type I error for that test (maximum Type I 
error=0.05).
All metric analyses were performed using SPSS 
version 18 for Windows (IBM Corporation, Armonk, NY, 
2009). Binomial confidence intervals were constructed 
using  Excel  (Microsoft  Office,  2010,  Microsoft 
Corporation, 2009)
Survival Analysis
For the subset of subjects in the survival analysis 
using the Penn TMA, an optimal cut-point for the M-score 
was determined by a receiver operating characteristic 
(ROC) analysis. Using the diagnostic likelihood ratio 
method as described by Pepe [22], we found that at an 
M-score cut-point of 10, the odds ratio (OR) for death 
achieved a maximum of 6.6. This value of the M-score 
was chosen to assign individuals to either a high FRA or 
low FRA expression category. The method of Kaplan-
Meier was used to estimate overall survival curves 
based on high or low FRA expression.  Multivariable 
cox proportional hazard models were used to adjust for 
potential confounding in the association between FRA 
level and overall survival. All survival analyses were Oncotarget 2012; 3:  414-425 418 www.impactjournals.com/oncotarget
performed in Stata 12 (StataCorp., College Station, TX).
RESULTS
Comparison of MAb 26B3 and Clone BN3.2 for 
Staining of Lung Carcinomas
There  is  significant  variation  in  the  literature 
with respect to the percent of various carcinomas that 
express FRA as determined by IHC, in part due to the 
use of a variety of antibodies, most of which are not 
commercially available. One FRA specific MAb that is 
commercially available and has been demonstrated to 
detect FRA on FFPE sections by IHC is clone BN3.2 
(Leica Microsystems, Buffalo Grove, IL) [20]. To assess 
the reproducibility between two distnct anti-FRA MAbs, 
we conducted IHC using clone BN3.2 and the recently 
developed MAb 26B3 for both specificity and sensitivity 
for the detection of FRA using the commercial TMA 
containing various histological types of lung cancer. Both 
antibodies were highly specific for adenocarcinoma as 
compared with other histologic subtypes, particularly 
squamous cell carcinoma (Figure 1). However, MAb 
26B3 was significantly more sensitive than clone BN3.2, 
identifying 26/36 (72%; M-score mean ± SD = 19.84 ± 
18.64) and 22/36 (61%; M-score mean ± SD = 11.38 ± 
14.25) adenocarcinoma samples, respectively (p<0.0001). 
These data suggest that under the conditions employed 
here that clone BN3.2 is significantly less sensitive than 
MAb 26B3 for detecting FRA expression on FFPE tissues 
and, as shown in Figure 2A, the relationship in observed 
M-scores on lung adenocarcinoma samples for these 
two MAbs is clearly non-linear. All subsequent analyses 
described in the present work were performed using MAb 
26B3, given its robust sensitivity in IHC under conditions 
described here. 
Figure 2: Comparison of M-scores for MAb 26B3 and clone BN3.2 for Lung Adenocarcinoma. 
A. Scatterplot (MAb 26B3 versus clone BN3.2) demonstrating the increased sensitivity of MAb 26B3 for the detection of FRA expression 
on FFPE samples. The relationship is clearly non-linear and is best described by the equation: y = 0.0152x2 + 0.0151x - 0.0181; R² = 0.8721
B. Scatterplot of M-scores determined using MAb 26B3 on duplicate cores of lung adenocarcinoma. The linear relationship is described 
by: y = 0.9999x - 0.6452; R² = 0.9926
Panel A
Panel BOncotarget 2012; 3:  414-425 419 www.impactjournals.com/oncotarget
Normal Tissue Staining Distribution for MAb 
26B3 
The pattern of FRA expression with MAb 26B3 
on a normal tissue TMA was consistent with previously 
published literature using a variety of other antibodies 
and techniques [20, 23]. Pancreas, thyroid, lung, salivary 
gland, kidney, hypophysis, cervix and breast showed 
variable expression (Table 1). In Figure 3, the staining 
pattern in normal tissues, exemplified in normal kidney 
and normal lung sections, is highly restricted to epithelial 
cells and typically apical in nature. Such a staining pattern 
is consistent with the proposed biological functions of 
FRA in normal tissue. For example, FRA distributed on 
the proximal tubules of the kidney is thought to scavenge 
filtered folates and recycle them into the circulation so 
they are not lost into the urine [24, 25]. Similarly, FRA 
expression on bronchiolar epithelium is thought to have 
anti-bacterial activity by sequestering folates away from 
colonizing bacteria [26-28]. 
FRA Discriminates Between Lung 
Adenocarcinomas and Lung Squamous Cell 
Carcinomas
We evaluated a total of 89 lung cancer samples on 
the commercial TMA: 36 (40%) were adenocarcinoma, 
32 (36%) were squamous cell carcinoma, 2 (2%) were 
adenosquamous carcinomas, and the remaining 19 (21%) 
were of a variety of other histologies (Table 2). The 
overall rates of FRA positivity varied substantially for 
each of the histologic subtypes. A significantly higher 
proportion of adenocarcinoma tumors were positive for 
FRA when compared to squamous cell carcinomas (72% 
TissueType
FRA Staining*
(Number FRA 
+/Total; 
Intensity)
Comments
Cerebrum 0/3
Cerebellum 0/3
Adrenal 0/3
Ovary 0/3
Pancreas 3/3; 2+ Limited to luminal borders of ductaland acinar cells
Thyroid 2/5; 1+ (sparse) Cytoplasmic staining in follicular cells
Hypophysis 3/3; 1+ Predominantly cytoplasmic
Testis 0/3
Breast 3/3; 1+/2+ Ductal cells w ith luminal and membrane staining
Spleen 0/3
Tonsil 0/3
Thymus 0/3
Bone Marrow 0/3
Lung 3/3; 2+ Staining in bronchial and alveolar cells
Heart 0/3
Esophagus 0/3
Stomach 0/2
Small Intestine 0/3
Colon 0/3
Liver 0/3
SalivaryGland 3/3; 3+ Ductal and acinar cells
Kidney 3/3; 3+ Luminal staining of proximal tubular cells
Prostate 0/3
Endometrium 0/3
Cervix 1/3; 1+ Endocervicalcells
SkeletalMuscle 0/3
Skin 0/3
Nerve 0/3
Mesothelium 0/3
* The table shows FRA staining results for multiple normal human tissue specimens and is displayed as
the number of FRA + specimens/total number of specimens analyzed for each tissue type. Each
specimen represents a unique individual. Intensity, noted as 3+ (strong), 2+ (moderate) or 1+ (weak) is
an averagestainingintensityacrossallpositivesamplesas determined bythereadingpathologist.
Table 1: FRA Expression (MAb 26B3) in Normal Human TissuesOncotarget 2012; 3:  414-425 420 www.impactjournals.com/oncotarget
versus 13%, p<0.0001).  Of the 4 positive squamous cell 
carcinoma samples, only 1 showed 3+ staining on both 
cores; 1 had intermediate (2+) staining on both cores and 
the other 2 were very weakly positive in a single core 
(5-10% of tumor cells at 1+). The two adenosquamous 
carcinoma samples present on this TMA were also shown 
to be positive for FRA, with staining (2+ - 3+) restricted 
to the adenocarcinoma portion of these samples (Figure 4). 
The staining of duplicate cores in the adenocarcinoma 
samples was very consistent, (Figure 2B), a reflection of 
the robustness of MAb 26B3 staining. An examination of 
M-scores by stage and grade within the adenocarcinoma 
histologic subtype indicated that neither stage nor grade of 
disease was associated with the degree of FRA expression 
(data not shown). 
The M-score distribution for FRA staining of lung 
adenocarcinoma and squamous cell carcinoma samples 
is shown in Figure 5. The mean (± SEM) M-scores for 
adenocarcinoma and squamous cell carcinoma samples 
stained with MAb 26B3 were 19.84 (± 18.64) and 1.39 
Variable
FRA negative
N (%)
FRA positive
N (%) Total P value2
TumorHistology
Normal 1 (10%) 9 (90%) 10
Squamous cell carcinoma 28 (87%) 4 (14%) 32 <0.0001
Largecell carcinoma 3 (60%) 2 (40%) 5
Small cell carcinoma 7 (87%) 1 (13%) 8
Neuroendocrinecarcinoma 4 (67%) 2 (33%) 6
Adenocarcinoma3 10 (16%) 28 (74%) 38
TumorGrade
Grade 1 1 (20%) 4 (80%) 5
Grade 2 5 (22%) 18 (78%) 23
Grade 3 4 (40%) 6 (60%) 10 0.517
TumorStage
Stage I 4 (29%) 11 (71%) 15
Stage II 2 (17%) 10 (83%) 12
Stage III + IV 4 4 (36) 7 (64) 11 0.563
Gender
Female 3 (18%) 14 (82%) 17
Male 7 (33%) 14 (67%) 21 0.46
1 US Biomax Lung Cancer TMA
2 p-values determined using Fisher’s exact test or chi-square test: squamous cell carcinoma 
versus adenocarcinoma p<0.0001; males versusfemale, p=0.46; stage, p=0.563; grade, p=0.517
3 Includes 2 adenosquamous cases, both positive for FRA in the adenocarcinoma portion only
4 Only 1 stage IV case
Table 2: Distribution of FRA Expression1
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Figure 3: FRA Expression in Normal Tissues. 
A. Normal lung tissue with 2+, moderate membrane staining on the surface of alveolar cells (40x). 
B. Normal kidney with 3+ strong, thick, membrane staining on the luminal borders of proximal convoluted tubular cells. Glomerular cells 
are negative (40x). Oncotarget 2012; 3:  414-425 421 www.impactjournals.com/oncotarget
(± 5.54), respectively (p<0.0001). The M-score for 
adenocarcinoma samples was also significantly higher 
when compared against all other lung cancer histologic 
types. In addition, we performed a Tree Analysis to 
determine the odds for the histology of the cancer being 
adenocarcinoma. An M-score >21.7 resulted in an odds 
ratio (OR) of 16, further demonstrating that FRA is 
predominately expressed in the adenocarcinoma histology 
(analysis not shown).
Fine  Needle  Aspiration  Provides  Sufficient 
Material for FRA Staining
FFPE  tissue  blocks  are  rarely  available  from 
patients diagnosed with late stage lung cancer, as surgical 
resections are not typically performed; however biopsies 
in these patients are usually performed via small core 
specimens  or  fine  needle  aspirates  (FNA).  Therefore, 
we assessed the suitability of FRA IHC using MAb 
26B3 on cytology material obtained by FNA. We used 
samples from nine late-stage adenocarcinoma patients 
diagnosed by cytological evaluation of a thoracic lymph 
node aspirate (Figure 6) and demonstrated that the rate 
of FRA positivity (63%) was comparable to that seen for 
the histological specimens assessed on the lung cancer 
TMA (Table 2). Although only a small sample size, these 
data suggest that cytologic specimens may be a suitable 
tissue source for determining FRA expression in late stage 
adenocarcinoma patients.
FRA Positivity and Survival in Lung 
Adenocarcinoma
Clinical characteristics and FRA expression 
results for the 55 subjects with newly diagnosed lung 
adenocarcinoma on the Penn TMA and included in 
the outcome analysis are listed in Table 3. The reading 
pathologist was blinded to the clinical information when 
analyzing the FRA staining. All subjects were treated 
with surgical resection. Of the 55 subjects, 30 (57%) 
were alive at five years. To determine if FRA expression 
was associated with overall survival, we first used ROC 
analysis to determine an optimal cut-off for the M-score, 
which identified an M-score of 10 as the FRA level that 
provided the best discrimination in overall survival. 
High FRA expression (M-score ≥10) was associated with 
improved overall survival (HR 0.39, 95% CI 0.18-0.85; 
Figure 7). Median survival for the low FRA expressers 
(M-score < 10) was 43.2 months. For the patients with 
high FRA expression (M-score ≥ 10), median survival was 
indeterminate because more than 50% of the subjects were 
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Figure 4: FRA Expression of papillary adenocarcinoma and adenosquamous carcinoma. 
A. Lung papillary adenocarcinoma with 70% of tumor cells showing 3+ membrane staining and 30% 2+ membrane staining (20x). 
B. Lung adenosquamous carcinoma. Whorls of squamous cells (arrows) are surrounded by tall columnar cells with 3+ membrane staining. 
Malignant squamous cells are entirely negative for membranous staining, although there is a weak cytoplasmic staining. (20x).
Variable Cases
Number 53
Meanage, years(SD) 63.4 (9.7)
Sex, n (%)
Male
Female
32 (60)
21 (40)
Race, n (%)
Caucasian
African-American
Asian
41 (77)
11 (21)
1 (2)
Stage, n (%)
IA
IB
IIA
IIB
IIIA
IIIB
17 (32)
15 (28)
4 (8)
3 (6)
9 (17)
4 (8)
FRA Expression, n (%)
M-Score ≥ 10
M-Score < 10
36 (68)
17 (32)
Table 3: Characteristics of Patients with Lung 
Adenocarcinoma on Penn TMAOncotarget 2012; 3:  414-425 422 www.impactjournals.com/oncotarget
still alive at the end of follow-up. Higher FRA expression 
remained significantly associated with overall survival 
after adjusting for stage, age, gender, and race (Table 4).
DISCUSSION 
Treatments for patients with non-small cell lung 
cancer have undergone a paradigm shift in the last 5 
years. Previously, the most critical clinical distinction 
was to discriminate between small cell carcinoma and 
NSCLC as there was no clear therapeutic or prognostic 
reason to differentiate between the heterogeneous tumors 
comprising NSCLC (predominately adenocarcinoma 
and squamous cell carcinoma). The emergence of 
targeted  therapies  for  specific  histologic  subtypes  of 
lung cancer has led to an improvement in survival 
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Figure 5: M-score Distribution of FRA Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma. M-scores 
by histology type for FRA expression by IHC using MAb 26B3 were calculated as described. The mean (± SEM) M–scores were 19.84 (± 
18.64) for adenocarcinoma and 1.39 (± 5.54) for squamous cell carcinoma, respectively (p<0.0001). 
Figure 6: FRA Expression in Lung Adenocarcinoma FNA samples. 
Staining of cell block material from lymph node FNAs with MAb 26B3 
demonstrates successful staining of FRA, with expression limited to epithelial 
cells in an apical distribution.Oncotarget 2012; 3:  414-425 423 www.impactjournals.com/oncotarget
rates in both recurrent and metastatic NSCLC. It is 
increasingly apparent that both pathologic analysis and 
molecular subtyping will be necessary in determining the 
appropriate therapy for individual patients. For example, 
bevacizumab, a monoclonal antibody targeting vascular 
endothelial growth factor, in combination with standard 
chemotherapy, improves survival in non-squamous 
histology, but is contraindicated in patients with squamous 
cell carcinoma [29, 30]. In addition, it has recently been 
shown that specific sub-histology is also important in 
determining response to chemotherapeutic agents such 
as gemcitabine (improved survival in squamous cell) and 
pemetrexed (improved survival in adenocarcinoma and 
large cell) [31]. 
The distinction between the various histologic 
subtypes in NSCLC remains an ongoing clinical 
challenge, particularly when only limited, cytology-based 
samples are available. Previous studies have demonstrated 
the precise distinction of various subtypes is particularly 
challenging in cytologic specimens such as fine needle 
aspirates of lymph nodes or primary lung lesions, due to 
limited tumor cellularity and the frequent absence of tissue 
architecture [32-34]. Most cytopathology laboratories 
currently employ an IHC panel in these cases as an 
adjunct to aid tumor sub-classification, including TTF-1, 
Napsin A (positive in adenocarcinoma), cytokeratin 5/6 
and P63 (positive in squamous cell carcinoma). Given 
the high level expression of FRA in adenocarcinoma, in 
contrast to its very limited expression in squamous cell 
carcinoma, the present data supports further studies on 
FRA expression and its potential inclusion in IHC panels 
used for sub-classification of NSCLC.
Most patients with early stage (I and II), and some 
with locally advanced disease (stage III), are treated by 
surgical resection with or without adjuvant chemotherapy. 
Although stage is the major determinant of prognosis, 
other factors are important in distinguishing the biology 
of these tumors. There has been a great deal of work in 
identifying molecular prognostic factors, with studies 
evaluating the role of factors such as gene copy number, 
mRNA expression, and most commonly, the role of protein 
expression using IHC [35, 36]. Previous studies in lung 
cancer with IHC markers have been largely inconsistent 
[36]. Thus, there is still a need to identify reliable and 
robust prognostic markers in this disease. 
Given that the expression of FRA is largely limited 
to adenocarcinoma, we chose to evaluate the prognostic 
value of this marker on this patient population. In our 
analysis, we found that higher FRA expression was 
associated with a more favorable prognosis following 
Figure 7: Overall Survival Curves for Lung Adenocarcinoma Patients by M-score. Patients with high FRA expression 
(M-score ≥ 10) survived for a longer period when compared with low FRA-expression (M-score < 10).
Variable HR (95% CI) P value
FRA expression (base model)1 0.39 (0.18-0.75) 0.018
Adjusted for:
Stage 0.39 (0.18-0.75) 0.018
Age 0.42 (0.19-0.94) 0.034
Gender 0.39 (0.18-0.86) 0.019
Race 0.40 (0.17-0.91) 0.029
A HR of less than 1 indicates that the factor is associated with better overall survival. Potential
confounders were added one covariate ata time.
1Hazardratio for FRA M-score ≥10 compared to M-score <10
Table 4: Multivariable Cox Regression Models Demonstrating Adjusted HR for Overall SurvivalOncotarget 2012; 3:  414-425 424 www.impactjournals.com/oncotarget
surgical resection for lung adenocarcinoma. This finding is 
consistent with a previous study of surgically resected lung 
adenocarcinoma in which FRA expression was assessed at 
the mRNA level using quantitative PCR [7].
The mechanisms of increased FRA expression in 
cancer and its potential effect on prognosis are not well 
understood. While folic acid/vitamin B9 is essential to 
all mammalian cells, given its critical role in 1-carbon 
metabolism and methylation of nucleotides, lipids 
and proteins, FRA is apparently not required since its 
expression in normal tissues is highly restricted and its 
function more distinct than the ubiquitously expressed 
reduced folate receptor (RFC) (19). FRA has been 
clearly demonstrated to be essential during embryonic 
development but its role in some terminally differentiated 
adult tissues is, at best, speculative. On the other hand, 
RFC is responsible for the sequestration of folate into 
cells and for folate homeostasis. The expression of FRA 
over and above the expression of RFC has been postulated 
to impart a growth advantage to cells expressing this 
receptor, in part because of the very high affinity of FRA 
for folates relative to the RFC which may be advantageous 
in low folate environments or in situations of accelerated 
metabolic rate or growth, as in malignant tissue. It is 
interesting to speculate, therefore, that FRA expression 
on tumor cells imparts a growth advantage to those cells, 
especially since they are rapidly dividing and thus have 
increased folate requirements. Other functions for FRA 
include folate independent mechanisms whereby the 
receptor is thought to participate in transformation and 
increased cell growth via signal transduction with Lyn 
kinase members (13).
The question remains however, as to whether the 
expression of FRA is causative or simply a bystander 
in the pathogenesis of cancer. The expression of FRA 
on adenocarcinoma of the lung correlates well with the 
expression of FRA on normal type I and II pneumocytes 
in that adenocarcinomas frequently arise from these 
cell types and thus supports the hypothesis that a FRA 
expressing tumor is a result of the cell of origin of that 
tumor naturally expressing this receptor. This is further 
supported by the lack of expression of FRA in squamous 
cell carcinoma which derives from more centrally located 
respiratory epithelium that are universally negative for 
FRA expression in normal tissue. The small number of 
FRA  expressing  squamous  cell  carcinomas  identified 
in the present study may represent a unique molecular 
subtype of NSCLC. The fact that not all adenocarcinomas 
appear to express FRA may be a result of assay sensitivity 
or, alternatively, FRA negative adenocarcinomas may 
represent a different epithelial cell of origin. Either way, 
FRA expression appears to identify a specific molecular 
subtype of lung adenocarcinoma. Additional studies may 
further elucidate not only the biology of FRA expression 
in lung adenocarcinoma but the prognostic significance 
of this receptor. Clinical trials currently underway in lung 
adenocarcinoma known to express FRA may help clarify 
this emerging area of investigation.
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